QuartrQuartr

CRDF: Phase II response and durability signals underpin a planned pan-RAS colorectal cancer phase III trial

Less than 1 min read

Onvansertib plus FOLFOXIRI/bev showed 70%+ ORR vs 42% in phase II RAS-mutated colorectal cancer, with median PFS unreached in the treatment arm. A phase III trial is planned for Q1 2027, pending funding.

Based on Cardiff Oncology, Inc. [CRDF] UBS Global Biopharma Conference 2026 Audio Transcript — Nov. 16 2026

Disclaimer